Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

Malcolm K. Brenner, Donna R. Rill, Robert C. Moen, Robert A. Krance, Joseph Mirro, W. French Anderson, James N. Ihle

Research output: Contribution to journalArticlepeer-review

876 Scopus citations


Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.

Original languageEnglish (US)
Pages (from-to)85-86
Number of pages2
JournalThe Lancet
Issue number8837
StatePublished - Jan 9 1993

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Gene-marking to trace origin of relapse after autologous bone-marrow transplantation'. Together they form a unique fingerprint.

Cite this